A month has gone by since the last earnings report for HCA Healthcare (HCA) . Shares have added about 9.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is HCA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. HCA Healthcare Beats on Q2 Earnings, Ups 2024 EPS View HCA ...

HCA Healthcare, Inc. (HCA) is aided by growing patient admissions, acquisitions of healthcare facilities, an effective virtual care services suite and a notable financial stand. Zacks Rank & Price Performance HCA currently sports a Zacks Rank #1 (Strong Buy). The stock has gained 37.1% in the past year. Image Source: Zacks Investment Research Favorable Style Score HCA Healthcare carries an impressive Value Score of A. Value Score helps find stocks that are undervalued. Back-tested results have shown so far ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: ZIM Integrated Shipping Services Ltd. (ZIM) : This logistics company has seen the Zacks Consensus Estimate for its current year earnings increasing 233% over the last 60 days. HCA Healthcare, Inc. (HCA) : This healthcare holding company has seen the Zacks Consensus Estimate for its current year earnings increasing 6.1% over the last 60 days. Marex Group plc (MRX) : This financial services platform provider has seen the Zacks Consensus ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, August 20: ZIM Integrated Shipping Services Ltd. (ZIM) : This logistics company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 233% over the last 60 days. ZIM Integrated Shipping Services has a price-to-earnings ratio (P/E) of 3.05 compared with 5.10 for the industry. The company possesses a Value Scoreof A. HCA Healthcare, Inc. (HCA) : This ...

When it comes to doing well in a recession, few names come to mind quicker than that of 'The Big Short' investor Michael Burry. Indeed, Burry proved his ability to correctly judge the weaknesses of the stock market and of the economy at a time when much of the world was caught by surprise in what would become known as the Great Recession. Though the hedge fund manager has not managed a success of the magnitude of his 'Big Short' in the last 16 years and has even taken some big losses with, for example, his ...

The stock market has witnessed weakness in recent weeks. Against such a backdrop, investors are increasingly exploring strategies that will help them protect their portfolios from downsides. Nothing seems better than the strategy of dividend investing. Picking stocks with a history of dividend growth leads to a healthy portfolio with a greater scope of capital appreciation as opposed to simple dividend-paying stocks or those with high yields. We have selected five dividend growth stocks — HCA Healthcare Inc ...

HCA Healthcare Today | --- | --- | |-----------------------|-------| | | | | | | | | | | HCA HCA Healthcare | | | $358.73 | | | +3.95 (+1.11%) | | | 52-Week Range $215.96 | | | ▼ | | | $361.12 | | | Dividend Yield 0.74% | | | P/E Ratio 17.88 | | | Price Target $341.12 | | | Add to Watchlist | | The nation's largest hospital operator, HCA Healthcare Inc. NYSE: HCA, surged to all-time highs following its strong Q2 2024 earnings results. The dramatic growth in acute care services has driven hospital stocks to ...

Part I. Financial Information [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents HCA Healthcare's unaudited condensed consolidated financial statements for periods ended June 30, 2024, detailing income, balance sheet, cash flows, and equity, with notes on accounting policies and key activities [Condensed Consolidated Income Statements](index=4&type=section&id=Condensed%20Consolidated%20Income%20Statements) Revenues for Q2 2024 increased to $17.49 billion, a 10.3% rise from Q2 2023, with net income attributable to HCA growing to $1.46 billion, or $5.53 per diluted share Q2 Financial Performance (2024 vs. 2023) | Metric | Q2 2024 | Q2 2023 | Change | | :--- | :--- | :--- | :--- | | **Revenues** | $17,492 M | $15,861 M | +10.3% | | **Net Income Attributable to HCA** | $1,461 M | $1,193 M | +22.5% | | **Diluted EPS** | $5.53 | $4.29 | +28.9% | Six Months Financial Performance (2024 vs. 2023) | Metric | Six Months 2024 | Six Months 2023 | Change | | :--- | :--- | :--- | :--- | | **Revenues** | $34,831 M | $31,452 M | +10.7% | | **Net Income Attributable to HCA** | $3,052 M | $2,556 M | +19.4% | | **Diluted EPS** | $11.47 | $9.14 | +25.5% | [Condensed Consolidated Balance Sheets](index=8&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2024, total assets were $57.38 billion, total debt stood at $40.88 billion, and stockholders' deficit improved to $1.60 billion Balance Sheet Summary (in millions) | Account | June 30, 2024 | Dec 31, 2023 | | :--- | :--- | :--- | | **Total Current Assets** | $15,173 | $14,927 | | **Total Assets** | $57,379 | $56,211 | | **Total Current Liabilities** | $14,301 | $12,655 | | **Long-term Debt** | $36,306 | $37,169 | | **Stockholders' Deficit (HCA)** | ($1,600) | ($1,774) | [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operating activities for the first six months of 2024 was $4.44 billion, with significant cash used in investing and financing activities, including share repurchases and dividends Six-Month Cash Flow Summary (in millions) | Activity | Six Months 2024 | Six Months 2023 | | :--- | :--- | :--- | | **Net Cash from Operations** | $4,440 | $4,278 | | **Net Cash used in Investing** | ($2,235) | ($2,408) | | **Net Cash used in Financing** | ($2,309) | ($1,923) | | **Change in Cash** | ($104) | ($46) | - Key financing activities in the first six months of 2024 included **$2.55 billion** in share repurchases and **$356 million** in dividend payments[46](index=46&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=14&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies and financial activities, including revenue recognition, acquisitions, debt, and segment performance, with the company operating 188 hospitals and other facilities - As of June 30, 2024, HCA and its affiliates owned and operated **188 hospitals**, **123 freestanding surgery centers**, and **23 freestanding endoscopy centers** across 20 states and England[49](index=49&type=chunk) Revenue by Payer - Six Months Ended June 30 (in millions) | Payer | 2024 | % of Total | 2023 | % of Total | | :--- | :--- | :--- | :--- | :--- | | Managed care and insurers | $17,094 | 49.0% | $15,453 | 49.2% | | Managed Medicare | $5,939 | 17.0% | $5,100 | 16.2% | | Medicare | $5,459 | 15.7% | $5,305 | 16.9% | | Medicaid | $2,108 | 6.1% | $1,477 | 4.7% | | Managed Medicaid | $2,011 | 5.8% | $1,807 | 5.7% | | Other | $1,392 | 4.0% | $1,558 | 4.9% | | International | $828 | 2.4% | $752 | 2.4% | | **Total Revenues** | **$34,831** | **100.0%** | **$31,452** | **100.0%** | - The estimated cost of total uncompensated care for the first six months of 2024 was **$2.08 billion**, up from **$1.73 billion** in the same period of 2023[30](index=30&type=chunk)[54](index=54&type=chunk) - During the first six months of 2024, the company paid **$50 million** to acquire two hospitals in Texas and **$81 million** for nonhospital entities, while receiving **$297 million** from the sale of a California hospital[31](index=31&type=chunk)[83](index=83&type=chunk) - In February 2024, HCA issued **$4.5 billion** in senior notes and in March 2024, repaid **$2.0 billion** of senior notes at maturity[67](index=67&type=chunk) - The company repurchased **8.111 million** shares of common stock in the first six months of 2024, with **$4.228 billion** remaining available under the January 2024 repurchase authorization[97](index=97&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=23&type=section&id=Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q2 and H1 2024 financial results, highlighting a 10.3% Q2 revenue increase driven by admissions and revenue per admission, covering revenue, volume, expenses, liquidity, and market risks [Results of Operations](index=24&type=section&id=Results%20of%20Operations) For Q2 2024, revenue grew 10.3% year-over-year, driven by increased admissions and revenue per admission, with net income rising 22.5% and improved salary and benefits as a percentage of revenue Key Performance Indicators - Q2 2024 vs Q2 2023 (% Change) | Metric | Consolidated Change | Same Facility Change | | :--- | :--- | :--- | | **Revenues** | +10.3% | +9.9% | | **Admissions** | +6.0% | +5.8% | | **Equivalent Admissions** | +6.0% | +5.2% | | **Revenue per Equivalent Admission** | +4.1% | +4.4% | - Salaries and benefits as a percentage of revenues improved to **43.9%** in Q2 2024 from **45.9%** in Q2 2023, primarily due to a **25.7%** year-over-year decline in contract labor costs[116](index=116&type=chunk) - Other operating expenses increased as a percentage of revenue to **20.7%** in Q2 2024 from **19.2%** in Q2 2023, mainly due to higher costs for professional fees and state provider fees[117](index=117&type=chunk) - The effective tax rate for Q2 2024 was **27.4%**, up from **24.9%** in Q2 2023, primarily due to adjustments to the liability for unrecognized tax benefits[169](index=169&type=chunk) [Revenue/Volume Trends](index=24&type=section&id=Revenue%2FVolume%20Trends) In Q2 2024, consolidated admissions grew by 6.0% and emergency department visits increased by 5.3%, with the estimated cost of total uncompensated care rising to $1.07 billion Volume Trends - Q2 2024 vs Q2 2023 (Consolidated % Change) | Metric | % Change | | :--- | :--- | | **Admissions** | +6.0% | | **Emergency Department Visits** | +5.3% | | **Inpatient Surgeries** | +2.6% | | **Outpatient Surgeries** | -1.8% | | **Uninsured Admissions** | +4.0% | - The estimated cost of total uncompensated care rose to **$1.072 billion** in Q2 2024 from **$899 million** in Q2 2023, and for the first six months, it was **$2.082 billion** in 2024 compared to **$1.730 billion** in 2023[109](index=109&type=chunk)[133](index=133&type=chunk) - Hospitals in Texas and Florida generated **51%** of the company's revenues and **59%** of its admissions in Q2 2024[111](index=111&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) The company generated $4.44 billion in cash from operations in H1 2024, with planned capital expenditures of $5.1 to $5.3 billion for the full year, confirming sufficient liquidity - Cash provided by operating activities for the first six months of 2024 was **$4.440 billion**, an increase of **$162 million** from the prior year period[124](index=124&type=chunk) - Capital expenditures are planned to be between **$5.1 billion** and **$5.3 billion** for the full year 2024[124](index=124&type=chunk) - As of June 30, 2024, HCA had **$7.137 billion** available under its senior secured credit facilities[124](index=124&type=chunk) - Management confirms that cash flows from operations, available credit, and access to debt markets are expected to be sufficient to meet liquidity needs for the foreseeable future[177](index=177&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) HCA is exposed to market risks from interest rate changes on its variable-rate debt and market value fluctuations of securities held by its insurance subsidiaries, with a hypothetical 1% interest rate increase reducing pretax earnings by $21 million annually - The company is exposed to interest rate risk, with **$2.125 billion** of its debt subject to variable rates as of June 30, 2024[178](index=178&type=chunk) - A hypothetical **1%** increase in interest rates would result in an estimated potential annualized reduction to future pretax earnings of approximately **$21 million**[178](index=178&type=chunk) - Investments held by insurance subsidiaries, valued at **$587 million**, are exposed to market value and illiquidity risks, with **$31 million** in unrealized losses as of June 30, 2024[178](index=178&type=chunk) [Item 4. Controls and Procedures](index=41&type=section&id=Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of June 30, 2024, with no material changes in internal control over financial reporting - The CEO and CFO concluded that HCA's disclosure controls and procedures were effective as of June 30, 2024[184](index=184&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[185](index=185&type=chunk) Part II. Other Information [Item 1. Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) The company operates in a highly regulated and litigious industry, subject to various lawsuits, claims, and governmental investigations, including whistleblower suits, which could materially affect financial results - As a healthcare company, HCA is subject to numerous lawsuits, claims, and legal proceedings, including government investigations and whistleblower suits, which are inherent to the industry[96](index=96&type=chunk)[160](index=160&type=chunk) [Item 1A. Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) No material changes were reported to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2023 - No material changes were reported to the risk factors disclosed in the 2023 Annual Report on Form 10-K[161](index=161&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q2 2024, HCA repurchased 4.22 million shares for $1.37 billion, with $4.228 billion remaining under authorization, and declared a quarterly dividend of $0.66 per share Share Repurchases - Q2 2024 | Month | Shares Purchased | Average Price Paid | | :--- | :--- | :--- | | April 2024 | 1,306,069 | $321.58 | | May 2024 | 1,784,870 | $317.63 | | June 2024 | 1,125,922 | $337.51 | | **Total Q2** | **4,216,861** | **$324.16** | - As of June 30, 2024, **$4.228 billion** of repurchase authorization was available under the January 2024 program[162](index=162&type=chunk) - On July 22, 2024, the Board of Directors declared a quarterly dividend of **$0.66 per share**, payable on September 30, 2024[163](index=163&type=chunk) [Item 6. Exhibits](index=42&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and financial statements formatted in Inline XBRL - The exhibits include CEO and CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act, and financial data formatted in Inline XBRL[165](index=165&type=chunk)[192](index=192&type=chunk)

Relative % Price change – 4 weeks greater than 0 Current Price greater than or equal to $5 and Average 20-day Volume greater than or equal to 50,000: A minimum price of $5 is a good standard to screen low-priced stocks, while a high trading volume would imply adequate liquidity. Notably, the Zacks Consensus Estimate for Seagate Technology's fiscal 2025 earnings per share indicates 352.7% year-over-year growth. The firm has a market capitalization of $22.1 billion. STX shares have gone up 89% in a year. Inte ...

Core Insights - Spotify's monthly active users (MAU) are projected to increase by 13 million in Q3, reaching 639 million, while subscribers are expected to rise by 5 million to 251 million [2] - Both HCA Healthcare and Spotify exceeded Q2 earnings expectations, indicating a promising investment opportunity due to their increased profitability [4] - Spotify's Q2 sales reached $4.09 billion, an 18% increase from $3.45 billion in Q2 2023, despite slightly missing estimates [5] - HCA's Q2 EPS increased by 28% to $5.50, surpassing the Zacks EPS Consensus of $4.97 by 10% [10] - Spotify's Q2 EPS was $1.43, a significant improvement from an adjusted loss of -$1.69 in the prior year, exceeding expectations by 32% [12] - Spotify achieved a gross margin of 29.2% and a record free cash flow of approximately $531.74 million [13][14] - Both companies are expected to see upward revisions in earnings estimates, with anticipated double-digit EPS growth for fiscal 2024 and FY25 [16] Company Performance - Spotify's stock has surged over 70% this year, while HCA's stock has increased by 26%, both outperforming the S&P 500's 17% gain [15] - HCA operates various healthcare facilities and has seen strong demand for its services across 20 states and the UK [9]